Marshall Hogarth, Ph.D., is an independent investigator in the Center for Genetic Medicine Research. Originally from New Zealand, Marshall's research training spans the entire spectrum of muscle function, from elite athletes to the general population and a broad range of genetic muscle diseases including inflammatory myopathies and muscular dystrophies. His postdoctoral studies established the role of tissue-resident mesenchymal stem cells, called fibroadipogenic progenitors (FAPs), in the progressive replacement of functional muscle fibers with fibrofatty deposits in muscular dystrophies. Marshall now leads a research team aimed at translating these findings into FAP-targeting therapies to arrest fibrofatty replacement of muscle and prevent the progression of muscle weakness in muscular dystrophies and other diseases which feature this pathogenic mechanism.
